Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Snyder

Showing results (671-680 of 1,178) with videos related to

Pageof 118
Sort By:
Journal of Neuro-Oncology|September 15, 2017
Erratum to: Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX statusRachel L Delfanti, David E Piccioni, Jason Handwerker, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 26, 1999
High-dose chemo/radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk advanced-stage Hodgkin's disease during first partial or complete remissionA Nademanee, A Molina, H Fung, et al.
Journal of Neuro-Oncology|September 6, 2017
Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX statusRachel L Delfanti, David E Piccioni, Jason Handwerker, et al.
Blood|February 26, 2000
Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factorsA Krishnan, S Bhatia, M L Slovak, et al.
Bone Marrow Transplantation|December 15, 2010
Phase-2 trial of an intensified conditioning regimen for allogeneic hematopoietic cell transplant for poor-risk leukemiaA S Stein, M R O'Donnell, T W Synold, et al.
The Lancet. Haematology|February 9, 2016
Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trialRyotaro Nakamura, Corinna La Rosa, Jeffrey Longmate, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 21, 1998
Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignanciesG D Long, M D Amylon, K E Stockerl-Goldstein, et al.
Haematologica|December 9, 2016
Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemiaJorge Cortes, Moshe Talpaz, Hedy P Smith, et al.
Blood Advances|September 28, 2021
Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label studyHaris Ali, Ni-Chun Tsai, Timothy Synold, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 1, 1996
Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host diseaseN J Chao, P M Parker, J C Niland, et al.
Pageof 118

Showing results (671-680 of 1,178) with videos related to

Sort By:
Pageof 118
Journal of Neuro-Oncology|September 15, 2017
Erratum to: Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX statusRachel L Delfanti, David E Piccioni, Jason Handwerker, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 26, 1999
High-dose chemo/radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk advanced-stage Hodgkin's disease during first partial or complete remissionA Nademanee, A Molina, H Fung, et al.
Journal of Neuro-Oncology|September 6, 2017
Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX statusRachel L Delfanti, David E Piccioni, Jason Handwerker, et al.
Blood|February 26, 2000
Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factorsA Krishnan, S Bhatia, M L Slovak, et al.
Bone Marrow Transplantation|December 15, 2010
Phase-2 trial of an intensified conditioning regimen for allogeneic hematopoietic cell transplant for poor-risk leukemiaA S Stein, M R O'Donnell, T W Synold, et al.
The Lancet. Haematology|February 9, 2016
Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trialRyotaro Nakamura, Corinna La Rosa, Jeffrey Longmate, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 21, 1998
Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignanciesG D Long, M D Amylon, K E Stockerl-Goldstein, et al.
Haematologica|December 9, 2016
Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemiaJorge Cortes, Moshe Talpaz, Hedy P Smith, et al.
Blood Advances|September 28, 2021
Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label studyHaris Ali, Ni-Chun Tsai, Timothy Synold, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 1, 1996
Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host diseaseN J Chao, P M Parker, J C Niland, et al.
Pageof 118